- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04800471
Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
Improving Glycemic Control and Clinical Outcomes in DM2 Patients in the Ambulatory Setting, a Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes is affecting millions of Americans. High glucose levels lead to complications such as heart attacks, stroke or blindness. Patients with diabetes need to exercise at least 150 min/week, a goal however that is not usually achieved. Reducing high glucose levels may unfortunately lead to very low glucose values-hypoglycemia, a condition that can lead to loss of consciousness or even death. Both of these conditions, high and low glucose levels, can therefore lead to visits to the Emergency department or hospitalizations. In fact, patients with diabetes have frequent admissions to the hospital. Additionally, many of them are admitted again, immediately or in less than 30 days after hospital discharge. Most of patients with diabetes are monitoring their glucose values with finger-stick glucose testing. Continuous Glucose Monitors (CGMs) are new devices that can monitor glucose continuously (every couple of minutes) without the need of finger-stick glucose testing. Similar to the glucometers, CGM devices can record glucose values, which can then be obtained by the clinicians, who can help them to modify DM medications. In addition to using CGM devices for diabetes management, smart insulin pens can be used in order to help with diabetes control. These devices can store and transfer data to the medical doctors, making them aware about the patients' glucose values. Moreover there are different health solutions available to manage patients including mobile health and telemedicine, which can help combining and transferring these data remotely. Briefly, telemedicine is a way to deliver healthcare where providers and patients communicate through alternative methods (telephone or other electronic method for example) instead of only traditional in-person office visits. Using telemedicine to replace some routine office visits can improve access to healthcare. It can also improve communication between patients and providers which is often a challenge to diabetes management. You may be able to more quickly and safely change medications to help the patients' diabetes control.
In this application we are going to examine whether utilizing telemedicine is a better communication tool between patients and providers and if it will lead to improved blood sugar control and increased exercise pattern compared to traditional monitoring with glucometers and in-person office visits only. We believe that this intervention may lead to better clinical outcomes.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: William Scott
- Phone Number: 4106057000
- Email: william.scott5@va.gov
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Baltimore VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Insulin-treated patients with DM2 (treated with basal-bolus insulin regimens (MDI), ± non-insulin medications) and Uncontrolled glycemic control
Exclusion Criteria:
- History of type 1 DM (DM1)
- Pregnant Patients
- Extensive skin changes/disease or allergies that preclude wearing the CGM sensor
- Subjects who have end-stage renal disease requiring dialysis
- Significant psychiatric illness or any other condition rendering the subject incapable of understanding the objectives and potential consequences of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Smart insulin pens and CGM
Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
|
Participants in this group will be monitored by Smart Insulin pens and Continuous Glucose Monitoring Devices
|
Placebo Comparator: Point of Care Glucose Group
Participants in this group will be monitored by point of care glucose values
|
Participants in this group will be monitored by POC glucose values.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in hyperglycemia
Time Frame: 3 months
|
Change in HbA1c
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in hyperglycemia
Time Frame: 6 months
|
Change in HbA1c
|
6 months
|
Change in hypoglycemia
Time Frame: 3 months
|
Change in hypoglycemic episodes (CGM glucose <70 mg/dl for at least 15 min)
|
3 months
|
Change in hypoglycemia
Time Frame: 6 months
|
Change in hypoglycemic episodes (CGM glucose <70 mg/dl for at least 15 min)
|
6 months
|
Change in clinically significant hypoglycemia
Time Frame: 3 months
|
Change in clinically significant hypoglycemic episodes (CGM<54 mg/dl at least 15 min)
|
3 months
|
Change in clinically significant hypoglycemia
Time Frame: 6 months
|
Change in clinically significant hypoglycemic episodes (CGM<54 mg/dl at least 15 min)
|
6 months
|
Change in Time in Range (70-180 mg/dl)
Time Frame: 3 months
|
Change in CGM glucose Time in Range (70-180 mg/dl)
|
3 months
|
Change in Time in Range (70-180 mg/dl)
Time Frame: 6 months
|
Change in CGM glucose Time in Range (70-180 mg/dl)
|
6 months
|
Change in Time Below Range (<70 mg/dl)
Time Frame: 3 months
|
Change in CGM Time Below Range (<70 mg/dl)
|
3 months
|
Change in Time Below Range (<70 mg/dl)
Time Frame: 6 months
|
Change in CGM Time Below Range (<70 mg/dl)
|
6 months
|
Change in Time Above Range (>180 mg/dl)
Time Frame: 3 months
|
Change in CGM Time Above Range (>180 mg/dl)
|
3 months
|
Change in Time Above Range (>180 mg/dl)
Time Frame: 6 months
|
Change in CGM Time Above Range (>180 mg/dl)
|
6 months
|
Change in Glucose Variability
Time Frame: 3 months
|
Change in Coefficient of Variation (CV)
|
3 months
|
Change in Glucose Variability
Time Frame: 6 months
|
Change in Coefficient of Variation (CV)
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00095543
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Smart insulin pens and CGM
-
Medtronic DiabetesCompletedType 1 Diabetes MellitusUnited States
-
University of PittsburghNational Institute on Aging (NIA); National Center for Complementary and Integrative...Completed
-
Oregon Health and Science UniversityRecruiting
-
Centre Hospitalier du LuxembourgCompletedDiabetes Mellitus, Type 1Luxembourg
-
Steen AndersenMedtronicCompletedType 1 Diabetes MellitusDenmark
-
Tandem Diabetes Care, Inc.Jaeb Center for Health ResearchRecruitingType 2 Diabetes Treated With InsulinUnited States, Canada
-
University of CambridgeUniversity of Oxford; University of EdinburghRecruitingCystic Fibrosis-related DiabetesUnited Kingdom
-
University of CambridgeNorfolk and Norwich University Hospitals NHS Foundation Trust; Barts & The... and other collaboratorsRecruiting
-
Sue BrownDexCom, Inc.; Roche DiagnosticsTerminatedType 1 Diabetes MellitusUnited States
-
Imperial College LondonLondon Ambulance ServiceTerminatedHypoglycemia | Diabetes Mellitus, Type 1 | Hypoglycemia UnawarenessUnited Kingdom